INTRODUCTION: Asthma severe imposes important economic burden on health systems, especially with the incorporation of new drugs. Recently, tezepelumab has been approved to prevent exacerbations in patients. This study explores the economically justifiable price of tezepelumab for preventing exacerbations in patients with severe asthma. MATERIALS AND METHODS: A static model was developed using the decision tree microsimulation to estimate the quality-adjusted life years of two interventions: a single intramuscular dose of tezepelumab versus not applying tezepelumab. This analysis was made during a time horizon of 50 year and from a third-payer perspective. RESULTS: Based on thresholds of U828, U5128, and U9 992 per QALY evaluated in this study, we established economically justifiable drug acquisition prices of U795, U835, and U3384 per dose of Tezepelumab. Tezepelumab not was cost-effective using a WTP of U828 and U5128. It only was cost effective at WTP of U9 992 per QALY. CONCLUSION: The economically justifiable cost for tezepelumab in Colombia is between U95 to U384 per dose, depending on the WTP used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.